Orphazyme A/S Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Orphazyme A/S in the last year. There are currently 2 sell ratings and 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "sell" Orphazyme A/S stock.
View analyst ratings for Orphazyme A/S or view top-rated stocks.

Wall Street analysts have given Orphazyme A/S a "Sell" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Orphazyme A/S wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Orphazyme A/S saw a increase in short interest during the month of May. As of May 28th, there was short interest totaling 35,300 shares, an increase of 141.8% from the May 13th total of 14,600 shares. Based on an average trading volume of 182,600 shares, the days-to-cover ratio is presently 0.2 days.
View Orphazyme A/S's Short Interest.

3 brokerages have issued 1 year price objectives for Orphazyme A/S's stock. Their forecasts range from $5.00 to $27.00. On average, they anticipate Orphazyme A/S's stock price to reach $16.00 in the next year. This suggests a possible upside of 145.4% from the stock's current price.
View analysts' price targets for Orphazyme A/S or view top-rated stocks among Wall Street analysts.

Some companies that are related to Orphazyme A/S include ChemoCentryx (CCXI), ESSA Pharma (EPIX), Travere Therapeutics (TVTX), G1 Therapeutics (GTHX), Nkarta (NKTX), RAPT Therapeutics (RAPT), Evelo Biosciences (EVLO), Epizyme (EPZM), OrganiGram (OGI), Arcturus Therapeutics (ARCT), Syndax Pharmaceuticals (SNDX), Merus (MRUS), ADVANZ PHARMA (CXRXF), Verastem (VSTM) and Zomedica (ZOM).
View all of ORPH's competitors.

(ORPH) raised $100 million in an initial public offering (IPO) on Tuesday, September 29th 2020. The company issued 7,600,000 shares at $13.13 per share. BofA Securities, Cowen and Guggenheim Securities served as the underwriters for the IPO and Danske Markets was co-manager.

Orphazyme A/S trades on the NASDAQ under the ticker symbol "ORPH."

Orphazyme A/S's stock is owned by a number of retail and institutional investors. Top institutional investors include Point72 Asset Management L.P. (0.38%), Millennium Management LLC (0.35%), Caas Capital Management LP (0.06%) and Point72 Hong Kong Ltd (0.01%).

ORPH stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, and Caas Capital Management LP.

ORPH stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., and Point72 Hong Kong Ltd.

Shares of ORPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ORPH stock can currently be purchased for approximately $6.52.

Orphazyme A/S has a market capitalization of $227.89 million. The company earns $-97,010,000.00 in net income (profit) each year or ($3.42) on an earnings per share basis.

Orphazyme A/S employs 141 workers across the globe.

The official website for Orphazyme A/S is www.orphazyme.com.

Orphazyme A/S is headquartered at OLE MAALOES VEJ 3, COPENHAGEN N G7, DK-2200.

Orphazyme A/S's mailing address is OLE MAALOES VEJ 3, COPENHAGEN N G7, DK-2200. The company can be reached via phone at 45 39 17 82 72 or via email at [email protected]